AU2008256562A1 - Combination of CHK and PARP inhibitors for the treatment of cancers - Google Patents

Combination of CHK and PARP inhibitors for the treatment of cancers Download PDF

Info

Publication number
AU2008256562A1
AU2008256562A1 AU2008256562A AU2008256562A AU2008256562A1 AU 2008256562 A1 AU2008256562 A1 AU 2008256562A1 AU 2008256562 A AU2008256562 A AU 2008256562A AU 2008256562 A AU2008256562 A AU 2008256562A AU 2008256562 A1 AU2008256562 A1 AU 2008256562A1
Authority
AU
Australia
Prior art keywords
alkyl
cancer
optionally substituted
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008256562A
Other languages
English (en)
Inventor
Mark James O'connor
Graeme Cameron Murray Smith
Sonya Zabludoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008256562A1 publication Critical patent/AU2008256562A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008256562A 2007-05-25 2008-05-23 Combination of CHK and PARP inhibitors for the treatment of cancers Abandoned AU2008256562A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94020307P 2007-05-25 2007-05-25
US60/940,203 2007-05-25
PCT/GB2008/050372 WO2008146035A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Publications (1)

Publication Number Publication Date
AU2008256562A1 true AU2008256562A1 (en) 2008-12-04

Family

ID=39672970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008256562A Abandoned AU2008256562A1 (en) 2007-05-25 2008-05-23 Combination of CHK and PARP inhibitors for the treatment of cancers

Country Status (11)

Country Link
US (1) US20100249112A1 (https=)
EP (1) EP2167086A1 (https=)
JP (1) JP2010527981A (https=)
KR (1) KR20100020981A (https=)
CN (1) CN101743003A (https=)
AU (1) AU2008256562A1 (https=)
BR (1) BRPI0811059A2 (https=)
CA (1) CA2687786A1 (https=)
MX (1) MX2009012705A (https=)
RU (1) RU2009147819A (https=)
WO (1) WO2008146035A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
PL2938598T3 (pl) 2012-12-31 2017-05-31 Cadila Healthcare Limited Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy)
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3609884A4 (en) 2017-04-10 2021-01-06 Sierra Oncology, Inc. CHK1 (SRA737) / PAPI COMBINATION METHOD FOR INHIBITION OF TUMOR GROWTH
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
CA3095709A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
WO2022000946A1 (zh) * 2020-06-29 2022-01-06 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN112375070B (zh) * 2020-06-29 2023-03-28 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
KR20260030809A (ko) 2023-06-21 2026-03-06 테트라곤 바이오사이언시스 엘티디 Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
KR20060123403A (ko) * 2003-12-01 2006-12-01 쿠도스 파마슈티칼스 리미티드 암 치료를 위한 ｄｎａ 손상 수복 억제제
BRPI0418351A (pt) * 2004-01-05 2007-05-08 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
EP1836320A2 (en) * 2005-01-07 2007-09-26 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage

Also Published As

Publication number Publication date
JP2010527981A (ja) 2010-08-19
WO2008146035A1 (en) 2008-12-04
RU2009147819A (ru) 2011-06-27
CN101743003A (zh) 2010-06-16
CA2687786A1 (en) 2008-12-04
MX2009012705A (es) 2009-12-08
US20100249112A1 (en) 2010-09-30
BRPI0811059A2 (pt) 2017-05-09
KR20100020981A (ko) 2010-02-23
EP2167086A1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
AU2008256562A1 (en) Combination of CHK and PARP inhibitors for the treatment of cancers
AU2004220321B2 (en) Phthalazinone derivatives
AU2010364807B2 (en) Heterocyclic derivates, preparation processes and medical uses thereof
AU2011288876B2 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
EP4421076A1 (en) Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
EP3418275B1 (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
CN106170289A (zh) 作为蛋白质激酶的调节剂的二芳基巨环
JP2008510783A (ja) ４−ヘテロアリールメチル置換フタラジノン誘導体
JP2009512671A (ja) ４−ヘテロアリールメチル置換されたフタラジノン誘導体
JP2010523633A (ja) フタラジノン誘導体および癌を治療するための医薬としてのその使用
JP2022524191A (ja) 大環状化合物
AU2008299721A1 (en) Phthalazinone derivatives
CN109715166A (zh) 癌症的治疗
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN115836077B (zh) 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
EP3878841B1 (en) Indazole kinase inhibitor and use thereof
US12404244B2 (en) Pan-KIT kinase inhibitor having quinoline structure and application thereof
CA3259052A1 (en) HETEROCYCLIC COMPOUNDS USED AS PI3K.ALPHA INHIBITORS.
HK40052071B (en) Pan-kit kinase inhibitor having quinoline structure and application thereof
HK40009984A (en) Erbb inhibitors and uses thereof
EP2164485A1 (en) Combination of checkponit kinase ( chk) and telangiectasia mutated (atm) inhibitors for the treatment of cancer
MX2008004913A (en) 4-heteroarymethyl substituted phthalazinone derivatives

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted